Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
Terminated · Phase 3 · NCT03259334
Conditions: Ulcerative Colitis
At a glance
- Research payments reported, 2025
- $507
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 380
About the trial
- Sponsor
- Shire
- Tested
- Ontamalimab (drug), Placebo (other)
- Dates
- Started 2018-02-09; completion 2020-10-23
- Results posted
- Yes
The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of participant-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).
From ClinicalTrials.gov, last updated 2021-06-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $507 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Inland Empire Liver Foundation $507
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.